Pharsight

Inomax patents expiration

INOMAX IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5873359 MALLINCKRODT HOSP Methods and devices for treating pulmonary vasoconstriction and asthma
Jan, 2013

(11 years ago)

US5485827 MALLINCKRODT HOSP Methods and devices for treating plumonary vasoconstriction and asthma
Jan, 2013

(11 years ago)

US5873359

(Pediatric)

MALLINCKRODT HOSP Methods and devices for treating pulmonary vasoconstriction and asthma
Jul, 2013

(10 years ago)

US5485827

(Pediatric)

MALLINCKRODT HOSP Methods and devices for treating plumonary vasoconstriction and asthma
Jul, 2013

(10 years ago)

US5558083 MALLINCKRODT HOSP Nitric oxide delivery system
Nov, 2013

(10 years ago)

US5558083

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery system
May, 2014

(10 years ago)

US5732693 MALLINCKRODT HOSP Pause control of nitric oxide therapy
Dec, 2016

(7 years ago)

US5752504 MALLINCKRODT HOSP System for monitoring therapy during calibration
Dec, 2016

(7 years ago)

US6125846 MALLINCKRODT HOSP Purge system for nitric oxide administration apparatus
May, 2017

(7 years ago)

US5752504

(Pediatric)

MALLINCKRODT HOSP System for monitoring therapy during calibration
Jun, 2017

(7 years ago)

US5732693

(Pediatric)

MALLINCKRODT HOSP Pause control of nitric oxide therapy
Jun, 2017

(7 years ago)

US6125846

(Pediatric)

MALLINCKRODT HOSP Purge system for nitric oxide administration apparatus
Nov, 2017

(6 years ago)

US8282966 MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide
Jun, 2029

(5 years from now)

US8431163 MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas
Jun, 2029

(5 years from now)

US8293284 MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide
Jun, 2029

(5 years from now)

US8795741 MALLINCKRODT HOSP Methods for treating patients who are candidates for inhaled nitric oxide treatment
Jun, 2029

(5 years from now)

US8846112 MALLINCKRODT HOSP Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation
Jun, 2029

(5 years from now)

US8846112

(Pediatric)

MALLINCKRODT HOSP Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation
Dec, 2029

(5 years from now)

US8282966

(Pediatric)

MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide
Dec, 2029

(5 years from now)

US8431163

(Pediatric)

MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas
Dec, 2029

(5 years from now)

US8293284

(Pediatric)

MALLINCKRODT HOSP Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide
Dec, 2029

(5 years from now)

US8795741

(Pediatric)

MALLINCKRODT HOSP Methods for treating patients who are candidates for inhaled nitric oxide treatment
Dec, 2029

(5 years from now)

US8573210 MALLINCKRODT HOSP Nitric oxide delivery device
Jan, 2031

(6 years from now)

US8776795 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(6 years from now)

US9408993 MALLINCKRODT HOSP Nitric oxide delivery device
Jan, 2031

(6 years from now)

US9265911 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(6 years from now)

US9295802 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(6 years from now)

US8291904 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(6 years from now)

US8776794 MALLINCKRODT HOSP Nitric oxide delivery device
Jan, 2031

(6 years from now)

US8573209 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(6 years from now)

US9265911

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(7 years from now)

US8776794

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device
Jul, 2031

(7 years from now)

US8776795

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(7 years from now)

US8291904

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(7 years from now)

US8573209

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(7 years from now)

US9295802

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(7 years from now)

US9408993

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device
Jul, 2031

(7 years from now)

US8573210

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device
Jul, 2031

(7 years from now)

US9279794 MALLINCKRODT HOSP Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide
Feb, 2034

(9 years from now)

US9279794

(Pediatric)

MALLINCKRODT HOSP Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide
Aug, 2034

(10 years from now)

US9770570 MALLINCKRODT HOSP Apparatus and method for monitoring nitric oxide delivery
May, 2036

(11 years from now)

US9770570

(Pediatric)

MALLINCKRODT HOSP Apparatus and method for monitoring nitric oxide delivery
Nov, 2036

(12 years from now)

Inomax is owned by Mallinckrodt Hosp.

Inomax contains Nitric Oxide.

Inomax has a total of 42 drug patents out of which 12 drug patents have expired.

Expired drug patents of Inomax are:

  • US5873359
  • US5485827
  • US5873359*PED
  • US5485827*PED
  • US5558083
  • US5558083*PED
  • US5732693
  • US5752504
  • US6125846
  • US5752504*PED
  • US5732693*PED
  • US6125846*PED

Inomax was authorised for market use on 23 December, 1999.

Inomax is available in gas;inhalation dosage forms.

Inomax can be used as a method of providing nitric oxide therapy to a patient by measuring and displaying an indication of the calculated delivery concentration of nitric oxide as compared to the desired delivery concentration of nitric oxide, a method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide, a method of providing nitric oxide therapy to a patient by verifying gas information of nitric oxide prior to delivery to patient, a method of purging a nitric oxide delivery system, prevention or treatment of reversible vasoconstriction by the inhalation of nitric oxide with an oxygen containing gas, a method of treating hypoxic respiratory failure by verifying gas information of nitric oxide prior to delivery to patient, a method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient, a method of providing a predetermined concentration of nitric oxide to a patient, a method of providing nitric oxide therapy to a patient.

The generics of Inomax are possible to be released after 03 November, 2036.

Drug Exclusivity Drug Exclusivity Expiration
M(M-167) Oct 09, 2018
M(M-132) Dec 21, 2013
Pediatric Exclusivity(PED) Jun 21, 2014

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 23 December, 1999

Treatment: Prevention or treatment of reversible vasoconstriction by the inhalation of nitric oxide with an oxygen containing gas; A method of providing a predetermined concentration of nitric oxide to a patient...

Dosage: GAS;INHALATION

How can I launch a generic of INOMAX before it's drug patent expiration?
More Information on Dosage

INOMAX family patents

Family Patents